Targeted Cancer Therapies: Their Use, Effectiveness And Cost Effectiveness In Real World Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$121,682.00
Summary
Cancer treatments come at a high price tag and are also released to the market earlier than ever before. The high costs can be a barrier to public funding and patient access and their early release means their risks and benefits are not fully understood, especially in the long-term. This project aims to examine the newer biological therapies - their use, costs and benefits in real-world clinical practice.
Melanoma Genetics: Clinical Translation Of The Germline-somatic Continuum
Funder
National Health and Medical Research Council
Funding Amount
$2,231,372.00
Summary
While new targeted and immune therapies can improve prognosis from metastatic melanoma, long-term survival for most patients remains elusive due to drug resistance or failure of the immune system to kill the tumour. There thus remains a significant need to improve early detection, monitoring of relapse, and treatment strategies, to increase survival and provide cures. My research vision addresses these three pillars of cancer research using innovative and cutting edge genetic approaches.
Could Pharmacological Restoration Of Mecp2 Levels Be Of Therapeutic Value In Rett Syndrome?
Funder
National Health and Medical Research Council
Summary
Rett syndrome is one of the commonest single gene cause of developmental disability in girls; 1:8500 Australian females are affected by the age of 12. There is currently no cure. Rett syndrome most commonly results from a fault in one copy of the Mecp2 gene on the X chromosome. The proposed research aims to identify medicines, already known to be safe in children and adults, which specifically improve the functioning of the Mecp2 gene. This should rapidly lead to targeted clinical treatments for ....Rett syndrome is one of the commonest single gene cause of developmental disability in girls; 1:8500 Australian females are affected by the age of 12. There is currently no cure. Rett syndrome most commonly results from a fault in one copy of the Mecp2 gene on the X chromosome. The proposed research aims to identify medicines, already known to be safe in children and adults, which specifically improve the functioning of the Mecp2 gene. This should rapidly lead to targeted clinical treatments for this condition.Read moreRead less
Translation Of Genomic Findings To Improve Outcomes In Patients With Myeloid Blood Cancers
Funder
National Health and Medical Research Council
Funding Amount
$1,913,403.00
Summary
Changes within the DNA of blood cancer cells are responsible for causing cancer, but also control the progression through various stages of blood cancers and regulate the response of patients to treatment. It is fundamentally important to not only understand these genetic changes at the molecular level, but also to use these findings to rationally design clinical treatments that target these genetic changes to improve outcomes for patients with blood cancers.
Therapeutic Induction Of Tertiary Lymph Nodes In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$995,010.00
Summary
Immunotherapy has been an important recent advance in cancer treatment by using the body's own immune cells to fight cancer. Although there have been unprecedented dramatic results, not all patients benefit, and most benefits are temporary. The cellular environment in which cancers are embedded is crucial for controlling treatment success. We aim to apply novel 'precision' therapies to this environment to expose the cancer and enable attack by immune cells for improved immunotherapy.
There is a need to improve early detection, monitoring of relapse, and treatments for melanoma, to increase long-term survival. My research vision is to use innovative and cutting edge approaches to conduct a range of complementary studies under three broad but inter-related themes: Theme 1 – Genetic predisposition to melanoma in the general population; Theme 2 – Genetic predisposition to melanoma in high-density families; Theme 3 – Somatic aberrations underlying melanoma development.
Developing Smart Nanomedicine To Enable Advanced Diagnosis And Stimuli-responsive Treatment For Atherosclerosis And Thrombosis
Funder
National Health and Medical Research Council
Funding Amount
$523,342.00
Summary
The early detection and accurate characterization of life-threatening diseases such as cardiovascular diseases are critical to the design of treatment. A therapeutic approach that provides an efficient treatment with minimal side-effects is highly desired by both patients and healthcare systems. This project aims to develop smart nanomedicine with incorporated diagnostic sensor and external stimuli-responsive treatment mechanisms for cardiovascular diseases.
The Use Of Real-World Evidence To Support Regulatory And Reimbursement Decisions
Funder
National Health and Medical Research Council
Funding Amount
$91,538.00
Summary
Traditionally, medicines are studied extensively in clinical trials before they are widely available. More recently, some medicines have been allowed to enter the market without complete data on their benefits and risks. This means that these issues can only be studied once a medicine is on the market and used in routine clinical practice; this is referred to as real-world evidence. This research evaluates if this evidence is sufficient to prove that a medicine is safe and that it works